Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM. Copyright © 2012 Elsevier Inc. All rights reserved.


Mark V Sherrid, Milla Arabadjian. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Progress in cardiovascular diseases. 2012 May-Jun;54(6):483-92

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 22687589

View Full Text